|
Pete Leone, most recently Senior Principal at PureTech Ventures, has held executive management positions over an 20-year career in biotechnology, pharmaceuticals, medical devices, and healthcare service delivery. He has hands-on international business experience in the US, Europe, and Asia. Pete was formerly President and CEO at Phenome Sciences (now Xanthus Life Sciences), a company that developed metabolic probes to predict drug safety and therapeutic response, technologies that lead to discovery of a drug in critical care and development of new cancer agents. Prior to Phenome, he was a founder and President of DigiTrace Care Services (now SleepMed), now a $60 million annual revenue company that employs Beth Israel-Deaconess licensed technology to treat CNS and sleep disorders. Pete was a Partner at Corporate Decisions, a strategy consulting firm now part of Mercer. He has an MBA from Stanford University and an undergraduate degree in Engineering Science and pre-medical studies from Dartmouth College. Previous consulting and direct experience included General Electric in engineering, Procter & Gamble in marketing, and Sandoz Pharmaceuticals. | 